Ποια είναι η τιμή για Accelerate Diagnostics, Inc. (AXDX)

Η τιμή για Accelerate Diagnostics, Inc. (AXDX) είναι $0.01005

Ποια είναι η κεφαλαιοποίηση αγοράς για Accelerate Diagnostics, Inc. (AXDX)

Η κεφαλαιοποίηση αγοράς για Accelerate Diagnostics, Inc. (AXDX) είναι $146.42K

Accelerate Diagnostics, Inc. (AXDX) Τιμή και Κεφαλαιοποίηση Αγοράς

Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in solutions for the rapid diagnosis of critical infections, with operations spanning the United States, Europe, and the Middle East. The company's primary offering is the Accelerate Pheno system, an advanced in vitro diagnostic platform. Paired with its dedicated test kit, the Accelerate PhenoTest, this system facilitates quick identification and antimicrobial susceptibility testing (AST) for pathogens responsible for severe or healthcare-associated infections, encompassing both Gram-positive and Gram-negative organisms. The PhenoTest is specifically designed to yield crucial ID and AST results for patients suspected of bacteremia or fungemia – life-threatening conditions marked by high morbidity and mortality risks. Established in 1982, the company initially operated as Accelr8 Technology Corporation before adopting its current name, Accelerate Diagnostics, Inc., in December 2012. Its corporate headquarters are located in Tucson, Arizona.

Η τιμή για AXDX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$375,410 $146.42K	NVDA	$5.470T	+3,735,424,003.27%
$306,691 $146.42K	AAPL	$4.468T	+3,051,651,609.02%
$286,515 $146.42K	GOOG	$4.174T	+2,850,899,570.57%
$253,960 $146.42K	MSFT	$3.700T	+2,526,969,915.91%
$195,912 $146.42K	AMZN	$2.854T	+1,949,374,957.18%

Η τιμή για AXDX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$375,410 $146.42K